FDA faces allegations over ‘capricious’ allergy drug approval

Endo and its subsidiary have challenged the FDA's approval of an application by BPI Labs and Belcher Pharmaceuticals | Dispute argues the FDA undermined regulatory frameworks and patent protection.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Medtech

Judge tears into ‘safe harbour’ ruling in heart valve system case

26 March 2024 Judge’s dissenting opinion challenges the interpretation of the safe harbour provision by the US Court of Appeals for the Federal Circuit | Decision concerns Meril's importation of transcatheter heart valve systems in a dispute with Edwards Lifesciences | Court majority upheld the district court's ruling favouring Meril.

Careers

Paul Hastings hires ex-FDA policy director

5 March 2024 Firm hires former Food and Drug Administration staffer from King & Spalding | Washington DC office gains nearly a decade of FDA experience.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

FDA faces allegations over ‘capricious’ allergy drug approval

More on this story

Editor's picks

Editor's picks

More features